Arrowhead Pharmaceuticals ($NASDAQ:ARWR) Inc., a leading biopharmaceutical company, closed at $36.46 yesterday evening after analyzing its financial ratios for investment purposes. This closing showed an increase of 0.94% from its prior closing price of $36.12. Arrowhead Pharmaceuticals focuses on developing innovative therapeutics to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to develop small molecule drugs that target disease-causing genes and can be used to treat a broad range of diseases. Arrowhead is also researching oncology, cardiovascular, liver, metabolic and neurological diseases, among others.
It is currently working on numerous clinical trials and has several potential therapies in the pipeline. Investors have been attracted to Arrowhead Pharmaceuticals’ potential in developing treatments for diseases with no existing therapies. Its stock has seen a considerable increase over the past few years, with its current stock price closing at $36.46 yesterday evening. Moving forward, Arrowhead Pharmaceuticals looks to continue to develop treatments and therapies for these diseases, with the potential to revolutionize the healthcare industry.
On Thursday, ARROWHEAD PHARMACEUTICALS stock opened at $36.4 and closed at $35.7, down by 2.1% from last closing price of 36.5. This indicates a lack of confidence in the company’s financial performance and a negative outlook for future growth. Investors will likely need to wait until additional information is released before any significant changes in the stock’s price occur. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Arrowhead Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Arrowhead Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Arrowhead Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Arrowhead Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Arrowhead Pharmaceuticals Intrinsic Value
At GoodWhale, we believe that analyzing financials is essential to make smart investment decisions. We recently analyzed ARROWHEAD PHARMACEUTICALS‘s financials and used our proprietary Valuation Line to calculate the intrinsic value of their share. We determined that the intrinsic value of ARROWHEAD PHARMACEUTICALS share is around $102.5. Currently, the stock is traded at $35.7, which is a 65.2% discount to the intrinsic value – meaning it’s undervalued. For investors who are willing to take on some risk, this could be a great opportunity to buy into the stock and benefit from potential upside. More…
Risk Rating Analysis
Star Chart Analysis
It also has a large marketing and sales force that helps it to sell its products to customers.
– Lin BioScience Inc ($TPEX:6696)
Sangamo Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel genomic therapies. The Company’s technology platform is based on zinc finger DNA-binding proteins (ZFPs). The Company’s product candidates are designed to target and modulate the activity of specific genes associated with disease. The Company’s lead product candidates include SB-525, which is in Phase III clinical trials for the treatment of hemophilia A, and SB-913, which is in Phase I/II clinical trials for the treatment of Mucopolysaccharidosis Type I (MPS I).
– Acer Therapeutics Inc ($NASDAQ:ACER)
Acer Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of therapies for serious rare and life-threatening diseases. The company’s lead product candidate, Etrasimod, is in clinical development for the treatment of ulcerative colitis, Crohn’s disease, and relapsing multiple sclerosis. Acer also has a portfolio of product candidates in various stages of development for the treatment of rare genetic disorders, including Duchenne muscular dystrophy, Friedreich’s ataxia, alpha-1 antitrypsin deficiency, and Gaucher disease.
– Innovation1 Biotech Inc ($OTCPK:IVBT)
Innovation1 Biotech Inc is a company that focuses on developing innovative treatments for diseases. The company has a market cap of 1.6M as of 2022 and a Return on Equity of -5.58%. The company’s market cap is the value of its outstanding shares of stock. The company’s ROE is a measure of how much profit it generates for shareholders.
Investing in Arrowhead Pharmaceuticals Inc. (ARRW) can be a smart decision for investors. The stock ended the day up 0.94% at $36.46, making it an attractive investment option.